Home › NDC Lookup › RxCUI directory › RxCUI 2741694

Doravirine 100 MG / islatravir 0.25 MG Oral Tablet — RxCUI 2741694

RxNorm drug concept · Semantic clinical drug
RxCUI 2741694 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2741694
Official nameDoravirine 100 MG / islatravir 0.25 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Doravirine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Pifeltro treats HIV-1 infection, but it does not cure HIV. It's always used together with other HIV medicines — never on its own. When taken consistently as part of a combination r...
  • What exactly does Pifeltro treat, and will it cure my HIV?
  • Good news — you can take Pifeltro with or without food, whichever works best for you. Studies show that food doesn't meaningfully change how much of the drug gets into your body. T...
  • Can I take Pifeltro with food, or does it have to be on an empty stomach?
📖 Read our full Doravirine guide →

🕸️ Concept Web — How Doravirine 100 MG / islatravir 0.25 MG Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Doravirine 100 MG / islatravir 0.25 MG Oral Tablet RxCUI 2741694

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Doravirine 2055755
    • Islatravir 2741688
    • Doravirine / islatravir 2741690
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Idvynso 2741695
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doravirine / islatravir Oral Tablet 2741693
    • Doravirine / islatravir Oral Product 2741691
    • Doravirine / islatravir Pill 2741692
    • Doravirine / islatravir Oral Tablet [Idvynso] 2741699
    • Idvynso Oral Product 2741697
    • Idvynso Pill 2741698
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doravirine 100 MG SCDC · 2055756
  • Islatravir 0.25 MG SCDC · 2741689
  • Doravirine / islatravir Oral Tablet SCDF · 2741693
  • Doravirine / islatravir Oral Product SCDG · 2741691
  • Doravirine / islatravir Pill SCDG · 2741692

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2741694 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-5092-01 30 TABLET, FILM COATED in 1 BOTTLE (0006-5092-01) IDVYNSO Merck Sharp & Dohme LLC 2026-04-23
00006-5092-59 14 TABLET, FILM COATED in 1 BOTTLE (0006-5092-59) IDVYNSO Merck Sharp & Dohme LLC 2026-04-23
Observed labelers: Merck Sharp & Dohme LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.